RVL Pharmaceuticals plc
RVLP · NASDAQ
6/30/2023 | 3/31/2023 | 12/31/2022 | 9/30/2022 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.01 | 0.07 | -0.12 | -0.24 |
| FCF Yield | -23.56% | -6.29% | -15.43% | -5.20% |
| EV / EBITDA | -255.08 | -25.45 | -11.98 | -13.27 |
| Quality | ||||
| ROIC | -29.24% | -10.43% | -10.00% | -10.40% |
| Gross Margin | 76.43% | 73.97% | 73.90% | 74.81% |
| Cash Conversion Ratio | 0.50 | 0.50 | 0.90 | 0.70 |
| Growth | ||||
| Revenue 3-Year CAGR | -33.77% | -37.65% | -34.62% | -40.52% |
| Free Cash Flow Growth | -84.05% | 58.43% | -69.26% | -607.11% |
| Safety | ||||
| Net Debt / EBITDA | -105.09 | -4.62 | -1.25 | 0.21 |
| Interest Coverage | -6.98 | -1.40 | -5.87 | 3.54 |
| Efficiency | ||||
| Inventory Turnover | 1.44 | 10.79 | 3.27 | 4.07 |
| Cash Conversion Cycle | -33.24 | -75.47 | -29.24 | -198.02 |